ProQR Therapeutics N.V. (PRQR) stock
PRQRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.15−0.03 (-2.54%)
Close on Nov 17, 2026Market cap $121.17MP/E –Yield –
ProQR Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
ProQR Therapeutics's ebitda for the twelve months ending Sep 30, 2022 was -€67.70M. For fiscal 2021 it was -€54.88M. The highest annual figure on record is -€26.52M in fiscal 2015.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | -€54.88M | – |
| FY2020 | Dec 31, 2020 | -€40.01M | – |
| FY2019 | Dec 31, 2019 | -€55.39M | – |
| FY2018 | Dec 31, 2018 | -€35.30M | – |
| FY2017 | Dec 31, 2017 | -€39.43M | – |
| FY2016 | Dec 31, 2016 | -€38.33M | – |
| FY2015 | Dec 31, 2015 | -€26.52M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2023 | Sep 30, 2023 | -€6.75M | – |
| Q2 FY2023 | Jun 30, 2023 | -€8.22M | – |
| Q1 FY2023 | Mar 31, 2023 | -€8.84M | – |
| Q3 FY2022 | Sep 30, 2022 | -€19.21M | – |
| Q2 FY2022 | Jun 30, 2022 | -€15.24M | – |
| Q1 FY2022 | Mar 31, 2022 | -€16.47M | – |
| Q4 FY2021 | Dec 31, 2021 | -€16.78M | – |
| Q3 FY2021 | Sep 30, 2021 | -€14.01M | – |
| Q2 FY2021 | Jun 30, 2021 | -€12.60M | – |
| Q1 FY2021 | Mar 31, 2021 | -€11.47M | – |
| Q4 FY2020 | Dec 31, 2020 | -€11.02M | – |
| Q3 FY2020 | Sep 30, 2020 | -€10.21M | – |
| Q2 FY2020 | Jun 30, 2020 | -€2.83M | – |
| Q1 FY2020 | Mar 31, 2020 | -€15.96M | – |
| Q4 FY2019 | Dec 31, 2019 | -€16.92M | – |
| Q3 FY2019 | Sep 30, 2019 | -€12.94M | – |
| Q2 FY2019 | Jun 30, 2019 | -€11.32M | – |
| Q1 FY2019 | Mar 31, 2019 | -€14.22M | – |
| Q4 FY2018 | Dec 31, 2018 | -€12.58M | – |
| Q3 FY2018 | Sep 30, 2018 | -€5.68M | – |
| Q2 FY2018 | Jun 30, 2018 | -€7.43M | – |
| Q2 FY2017 | Jun 30, 2017 | -€9.91M | – |
See a number that looks wrong?